Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : VOLTAIRE'S PORCH-MODERATED -- Ignore unavailable to you. Want to Upgrade?

To: stockman_scott who wrote (39198)	7/18/2001 11:22:07 AM
From: Jim Willie CB	Read Replies (1) \| Respond to of 65232

yes, many little biotech gems on the beach but human intervention makes the sector so difficult 1. FDA FDA approval has now become more drawn out than ever and FDA process itself has become fickle and treacherous they change rules in midstream all the time numerous examples in my mammory if these guys wake up without proper mood or sated animal drives, they can destroy a company by changing the rules (saw that with Sunset and 80% drop, owned by friend, after they decided arbitrarily to extend reqmt from 9 to 18 months) 2. human subjects if any drug has revealed failures or unwanted side effects, then school is out the company stock is destroyed even distorted bad press is destuctive (saw that with Viagra and sudden bad press in 2000, all false) 3. political interference if political leaders DECIDE to commandeer, usurp, expropriate all intellectual property on the Human Genome, for the greater good, what of Celera of Human Genome Sciences? (saw that in summer 2000 when Jerkwad Clinton made pronouncements without thinking about the dozens of billion$ involved) plenty of opps to be sure in biotech I hate its agency, human, and political twists / jw